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Background. Clinical deterioration after initiation of antiretroviral therapy may result from restored immunity.
There is no standard clinical definition for immune reconstitution syndrome. The objectives of this study were
to validate a proposed definition and to identify factors predictive of immune reconstitution syndrome.
Methods. This was a retrospective case-control study from an academic university medical practice. Cases were
matched to 2 control subjects by CD4+ cell count at the time of initiation of antiretroviral therapy. Cases and
“mock cases” were blindly reviewed by 2 human immunodeficiency virus (HIV) experts.
Results. Twenty possible cases of immune reconstitution syndrome were identified; HIV experts excluded all
cases of herpes zoster (shingles), with agreement on real and mock cases of 92%. For 14 confirmed case patients
(compared with 40 control subjects), immune reconstitution syndrome was associated with a higher number of
prior opportunistic infections ( ) and higher CD8+ cell counts at baseline ( ) and at week 12Pp .003 Pp .05
( ). Immune reconstitution syndrome was associated with lower baseline levels of alanine aminotransferasePp .02
( ) and hemoglobin ( ). On multivariate analysis, the number of prior opportunistic infections (oddsPp .05 Pp .02
ratio, 2.7; ) and lower hemoglobin level at baseline (odds ratio, 0.8; ) were independentlyPp .007 Pp .003
associated with development of immune reconstitution syndrome. A predictive model was defined by classification
and regression tree analysis with a sensitivity and specificity of 78.57% and 87.50%, respectively, for an importance
score of 4 (on a scale of 0.0 to 100.0), and 92.86% and 80.00%, respectively, for a score of 2, using the number
of prior opportunistic infections, CD8+ cell count, and hemoglobin level.
Conclusions. A standard definition for immune reconstitution syndrome is possible. Patients with a greater
severity of illness at initiation of antiretroviral therapy are at risk for immune reconstitution syndrome. The model
defined by classification and regression tree analysis may provide a basis for risk stratification before initiation of
antiretroviral therapy.
The introduction of combination antiretroviral therapy
has dramatically improved outcomes for persons living
with HIV infection. Successful suppression of viral rep-
lication is followed by an increase in CD4+ lymphocytes
and a partial recovery of T cell–specific immune re-
sponses, which correlates with decreased susceptibility
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to opportunistic pathogens [1]. Some persons, however,
experience a clinical deterioration following initiation
of antiretroviral therapy that is believed to be a con-
sequence of the restored ability to mount an inflam-
matory response. This phenomenon has been termed
immune reconstitution syndrome, immune restoration
disease, immunorestitution disease, or immune recon-
stitution inflammatory syndrome. Immune reconsti-
tution syndrome has been reported in association with
a number of diseases and inflammatory conditions [2,
3]. In many cases, immune reconstitution syndrome
may be mild and resolve without treatment. Deaths,
however, have been reported, particularly in cases in
which there is CNS involvement with progressive mul-
tifocal leukoencephalopathy or infection with Crypto-
coccus species or Mycobacterium tuberculosis [3–5]. Be-
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cause the manifestations of immune reconstitution syndrome
vary widely, depending on the target to which the restored
inflammatory response is directed, it is difficult to describe as
a single clinical entity. The incidence of this disorder has been
estimated to be 10% among persons starting antiretroviral ther-
apy and as high as 25% among patients starting therapy who
have a CD4+ cell count of !50 cells/mm3 [6]. The true incidence
of immune reconstitution syndrome, however, is yet to be de-
termined, in part because no consensus has been achieved re-
garding a clinical definition.
It is important to define immune reconstitution syndrome
as a clinical entity to facilitate diagnosis and further charac-
terization of this disease. Identification of risk factors associated
with the development of immune reconstitution syndrome may
make it possible to characterize a population of patients that
may benefit from preemptive treatment with anti-inflammatory
agents. The objectives of this study were to validate a proposed
clinical definition of immune reconstitution syndrome and to
determine clinical or routine laboratory factors associated with
its development.
MATERIALS AND METHODS
In a retrospective case-control study, cases of presumed im-
mune reconstitution syndrome and control subjects were iden-
tified from records of patients at the University of Cincinnati
Infectious Disease Center who started taking combination an-
tiretroviral therapy between 1996 and 2002. All records of per-
sons who initiated antiretroviral therapy during this time period
were reviewed to determine whether an opportunistic illness
developed subsequent to starting therapy. To define cases of
immune reconstitution syndrome, we used the following mod-
ification of criteria proposed by a working group in the AIDS
Clinical Trials Group: new onset or worsening symptoms of an
infection or inflammatory condition following the initiation of
antiretroviral therapy; symptoms not explained by a newly ac-
quired infection, the predicted course of a previously diagnosed
infection, or the adverse effects of drug therapy; and demon-
stration of a1-log decrease in the number of HIV RNA copies
( Judith, Feinberg, personal communication). Control subjects
were HIV-infected patients who did not develop clinical events
consistent with the proposed study definition for immune re-
constitution syndrome. Each control subject was matched to a
case patient by CD4+ cell count and year of enrollment in the
clinic. Twenty possible case patients with immune reconstitu-
tion syndrome were identified and matched to 40 control sub-
jects. Data for case patients and control subjects were abstracted
by 2 authors (M.M. and J.W.) and were reviewed by a senior
author (C.J.F.) for accuracy. A blinded panel of 2 infectious
disease experts with 115 years of experience in treating persons
with AIDS reviewed the cases to determine their validity. To
avoid bias and to validate the proposed definition of immune
reconstitution syndrome, 4 “mock cases” were created (by J.W.
and C.J.F.) to represent classical presentations of common op-
portunistic infections (2 cases of dermatomal zoster and 1 case
each of cryptococcal meningitis and Mycobacterium avium
complex infection). Mock cases were chosen to ensure that
sufficient data were available to render an opinion and represent
diseases commonly seen at the clinic. Experts received a case
summary and laboratory information with the instruction that
although there is no widely accepted definition of immune
reconstitution syndrome, consensus opinion suggests that a re-
sponse to antiretroviral therapy is required at a minimum. Ex-
perts were then asked to render an opinion for each case re-
garding whether or not it represented a case of immune
reconstitution syndrome. Demographic data, history of op-
portunistic infections, and a baseline symptom history were
abstracted for each case patient. Data from complete blood cell
counts and liver enzyme tests were collected for the period
prior to initiation of antiretroviral therapy for all control sub-
jects and case patients and at the time of presentation of im-
mune reconstitution syndrome for case patients. HIV load,
CD4+ cell count, and CD8+ cell count data were collected for
intervals corresponding to baseline (before initiation of anti-
retroviral treatment) and 4–12 weeks, 12–16 weeks, and 16–28
weeks after the start of therapy.
Data were analyzed for differences between case patients and
control subjects with respect to baseline demographic infor-
mation, complete blood cell count, liver enzyme measurements,
and symptoms. HIV load, CD4+ cell count, CD4+ cell per-
centage, CD8+ cell count, CD8+ cell percentage, change in CD4+
or CD8+ cell count, and ratio of CD4+ to CD8+ cell counts
were analyzed at baseline and at each time interval. All statistical
analyses were performed using SAS software, version 8.2 (SAS),
with x2 or Fisher’s exact tests for categorical variables and the
Wilcoxon rank-sum test for continuous variables. Variables en-
tered into the multivariate model required a P of !.1. Multi-
variate analysis was performed using stepwise logistic regres-
sion. Classification and regression tree (CART) analysis was
used to identify subgroups of patients with a higher likelihood
of a diagnosis of immune reconstitution syndrome, using mul-
tiple significant predictors from the multivariate analysis [7].
The accuracy of CART for prediction of immune reconstitution
syndrome was analyzed using a receiver operating characteristic
curve. CART analysis was performed using CART software,
version 5.0 (California Statistical Software), and the receiver
operating characteristic curve was plotted using SPLUS, version
6.0 (Insightful).
RESULTS
Case definition. Twenty cases meeting the proposed study
definition of immune reconstitution syndrome were initially
identified. Four mock cases were added. HIV expert reviewers
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Table 1. Cases of immune reconstitution
syndrome, by diagnosis.
Diagnosis, by etiologic agent
No. (%)
of cases
Mycobacterium avium complex
Osteomyelitis 1 (7)
Pneumonia 2 (14)
Focal lymphadenitis 4 (29)
Disseminated infection 2 (14)
Total 9 (64)
Cytomegalovirus
Colitis 1 (7)
Total 1 (7)
Mycobacterium tuberculosis
Pneumonia 1 (7)
Total 1 (7)
Cryptococcus species
Meningitis 2 (14)
Focal lymphadenitis 1 (7)
Total 3 (21)
agreed on 92% of 24 total cases that were reviewed. There
was disagreement on 2 cases. One expert misidentified a single
mock case as being consistent with immune reconstitution
syndrome. This simulated case involved a patient with a di-
agnosis of biopsy-confirmed lymphadenitis due to M. avium
complex that involved multiple lymph node groups. This case
was characterized by no significant change in CD4+ cell count
(from 5 to 8 cells/mm3) and an increase in HIV load from
265,355 to 599,364 copies/mL following initiation of antiret-
roviral therapy. The second disagreement involved a patient
with culture-negative inflammatory meningitis following ini-
tiation of antiretroviral therapy that met the proposed study
definition of immune reconstitution syndrome. This patient
had a prior diagnosis of cryptococcal meningitis, which was
being treated. The inflammatory meningitis was concurrent
with an increase in CD4+ cell count and a decrease in HIV
RNA level in response to antiretroviral therapy. One expert
excluded the case because the time interval between initiation
of therapy and the event was thought to be too long. The
immune reconstitution syndrome event occurred 5 months af-
ter initiation of antiretroviral therapy. The patient’s regimen,
however, had been changed 2 weeks before the event, because
the patient was experiencing virological failure. This case was
included in the final analysis of cases. The 2 HIV experts ex-
cluded all 6 cases of herpes zoster (shingles), because the oc-
currence of this disease could not be distinguished from typical
cases of shingles observed in persons with lower CD4+ cell
counts not treated with antiretroviral therapy. The remaining
14 confirmed cases are summarized by diagnosis in table 1.
Baseline characteristics. Sex, age, ethnicity, and baseline
symptoms did not differ significantly between case patients and
control subjects (table 2). There was a higher median number
of prior opportunistic infections among the case patients than
among the control subjects (1.5 infections vs. 1.0 infection)
that was highly significant ( ). There was a nonsignif-Pp .003
icant trend toward higher frequency of protease inhibitor use
and history of an AIDS-defining illness in case patients (Pp
and , respectively). Baseline alanine aminotrans-.063 Pp .088
ferase levels (table 3) were significantly lower among case-
patients than among control subjects ( ), as were he-Pp .045
moglobin levels ( ), hematocrits ( ), RBCPp .023 Pp 024
counts ( ), and lymphocyte percentages ( ).Pp .014 Pp .012
Lymphocyte and viral load data. There were no significant
differences between case patients and control subjects with re-
spect to baseline CD4+ cell count (figure 1), indicating appro-
priate matching. Similarly, the interval CD4+ cell counts were
not different, with the exception of the CD4+ cell percentage
at week 12, which was significantly higher in case patients
( ). CD8+ cell counts were significantly lower amongPp .029
case patients at baseline ( ), week 12 ( ), andPp .048 Pp .017
week 28 ( ) and week 16 ( ). The ratio of CD4+Pp .048 Pp .052
to CD8+ cell counts was significantly higher in case patients at
week 12 ( ). There was no significant difference be-Pp .025
tween case patients and control subjects with respect to change
in CD4+ or CD8+ cell count by week 12. In case patients with
immune reconstitution syndrome ( ), a median 5-lognp 13
decrease (range, 6269 copies/mL to 999,678 copies/mL) in
the number of HIV RNA copies from baseline to week 12 was
observed. Adequate virological response was observed in both
case patients and control subjects, with no significant differ-
ences observed with respect to baseline viral load, interval viral
load, or change in viral load at week 12 (data not shown).
Multivariate analyses. Variables included in the multivar-
iate analysis were number of prior opportunistic infections;
baseline hemoglobin level, CD8+ cell count, alanine amino-
transferase level, and absolute lymphocyte count; and protease
inhibitor use. The number of prior opportunistic infections
(OR, 2.7; 95% CI, 1.3–5.4; ) and hemoglobin level atPp .007
baseline (OR, 0.8; 95% CI, 0.7–0.9; ) were indepen-Pp .003
dently associated with the likelihood of immune reconstitution
syndrome on multivariate analysis. Models using 3 or 4 of these
variables did not significantly alter the results.
CART analysis and receiver operating characteristic curve.
Four variables—the number of prior opportunistic infections,
baseline hemoglobin level, baseline CD8+ cell count, and use
of protease inhibitors—were assessed in a CART model to dis-
tinguish patients with or without immune reconstitution syn-
drome. The number of prior opportunistic infections and he-
moglobin level at baseline were chosen because they had shown
significance in both the multivariate analysis and the Wilcoxon
rank-sum test. The other 2 variables, CD8+ cell count at baseline
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Table 2. Baseline characteristics of case patients and control subjects in a study of
immune reconstitution syndrome.
Characteristic
Case patients
(n p 14)
Control subjects
(n p 40) P
Age, median years 40 38 .226
Median no. of symptoms 2.5 2.0 .500
Median no. of previous opportunistic infections 1.5 1.0 .003
History of AIDS-defining illness 11 21 .088
Protease inhibitor in regimen 11 20 .063
Male sex 13 38 .763
Race .421
White 5 21
African American 9 19
NOTE. Data are no. of patients, unless otherwise indicated.
Table 3. Baseline laboratory values for case patients and control subjects in a study of immune
reconstitution syndrome.
Measure
Case patients
(n p 14)
Control subjects
(n p 40) P
Alanine aminotransferase level, U/L 22 (11–95) 35 (11–220) .045
Aspartate aminotransferase level, U/L 36 (19–115) 31 (14–114) .332
Albumin level, g/dL 3.7 (1.8–4.5) 3.8 (2.4–4.8) .212
Alkaline phosphatase level, U/L 95 (43–155) 85 (42–143) .132
Bilirubin level, mg/dL 0.40 (0.1–0.6) 0.40 (0.1–0.8) .087
Total protein level, g/dL 7.25 (5.6–7.9) 7.50 (5.9–9.8) .092
WBC count, cells  103/mL 3.55 (2.4–6.5) 3.43 (1.2–15.1) .224
Hematocrit, % 0.323 (0.243–0.409) 0.362 (0.234–0.447) .024
Hemoglobin level, g/dL 10.95 (8.3–13.5) 12.30 (2.81–14.9) .023
RBC count, cells  106/mL 3.645 (2.80–4.75) 4.180 (2.81–5.07) .014
Platelets, cells  103/mL 217.5 (97–371) 194.0 (94–472) .198
Neutrophils, % 0.63 (0.41–0.85) 0.59 (0.22–0.91) .074
Lymphocytes, % 0.130 (0.020–0.290) 0.195 (0.05–0.50) .012
Monocytes, % 0.08 (0.07–0.17) 0.09 (0.01–0.026) .398
Basophils, % 0.003 (0.000–0.010) 0.002 (0.000–0.020) .422
Eosinophils, % 0.013 (0.000–0.230) 0.030 (0.00–0.350) .287
HIV RNA level, copies/mL 373,096 (6668–1,000,000) 296,343 (2276–1,569,426) .816
NOTE. Data are expressed as median (range).
and use of a protease inhibitor, had shown significance in the
Wilcoxon rank-sum tests.
In the CART analysis, use of a protease inhibitor was found
to be of least importance in predicting immune reconstitution
syndrome (importance score of 8.10 on a scale of 0.00–100.00)
and, thus, was excluded from the tree. The remaining 3 pre-
dictors were used to identify subjects with a higher likelihood
of having a diagnosis of immune reconstitution syndrome. The
results are shown in figure 2. A clinical scoring system based
on the 3 predictors used in CART could be developed by clas-
sifying patients from the least likely to develop immune re-
constitution syndrome (a score of 0) to the most likely to
develop immune reconstitution syndrome (a score of 4). The
receiver operating characteristic curve (figure 3) showed that
the sensitivity and specificity for predicting immune reconsti-
tution syndrome were 78.57% and 87.50%, respectively, for a
score of 4, and 92.86% and 80.00%, respectively, for a score
of 2.
DISCUSSION
Immune reconstitution syndrome can manifest with a wide
variety of clinical symptoms, depending on the target of the
inflammatory response. It is difficult to define as a single clinical
entity. In this study, we were successful in validating a proposed
definition of immune reconstitution syndrome, because it was
confirmed by a blinded panel of reviewers (92% overall agree-
ment). The 1 notable exception was dermatomal herpes zoster,
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Figure 1. Change in CD4+ cell count, CD4+ cell percentage (CD4%), CD8+ cell count, CD8+ cell percentage (CD8%), and ratio of CD4+ to CD8+ cells
(CD4/CD8 ratio) versus number of weeks of therapy. Statistically significant differences ( ) between case patients and control subjects wereP ! .05
observed for CD4+ cell percentage at week 12; CD8+ cell count at baseline, week 12, and week 28; and ratio of CD4+ to CD8+ cells at week 12.
presumed to be a manifestation of immune reconstitution syn-
drome. Reviewers rejected zoster as a manifestation of immune
reconstitution syndrome, because herpes zoster may manifest
irrespective of the host’s ability to generate an inflammatory
response, and there is no established way to clinically distin-
guish cases occurring as a result of immune reconstitution from
cases occurring coincidentally following the administration of
antiretroviral therapy. Herpes zoster was previously reported to
develop at a constant rate, regardless of the degree of immu-
nosuppression, although it has been shown to increase in in-
cidence 2-fold to 5-fold among HIV-infected patients treated
with antiretroviral therapy [8–11]. In contrast, Gebo et al. [12]
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Figure 2. Classification and regression tree (CART) analysis for the assessment of the clinical diagnosis of immune reconstitution syndrome. The
importance score equals 0 if there is 1 opportunistic infection; the importance score equals 1 if there is 11 opportunistic infection, baseline CD8+
cell count is 1468.5 cells/mm3, and baseline hemoglobin level is 110.2 g/dL; the importance score equals 2 if there is 11 opportunistic infection,
baseline CD8+ cell count is 1468.5 cells/mm3, and baseline hemoglobin level is 10.2 g/dL; the importance score equals 3 if there is 11 opportunistic
infection, baseline CD8+ cell count is 468.5 cells/mm3, and baseline hemoglobin level is 113.6 g/dL; and the importance score equals 4 if there is
11 opportunistic infection, baseline CD8+ cell count is 468.5 cells/mm3, and baseline hemoglobin level is 13.6 g/dL. Basal CD8, baseline CD8+
cell count; Basal HgB, baseline hemoglobin level; IRS, immune reconstitution syndrome; OI, opportunistic infection.
reported the overall incidence of herpes zoster to be similar in
the pre- and post-HAART eras. Further research will be re-
quired to determine whether there are unique pathological dif-
ferences in herpes zoster occurring in the setting of antiret-
roviral administration and immune reconstitution.
We have demonstrated that immune reconstitution syn-
drome can be defined as a clinical entity by the following mod-
ification of criteria proposed by a working group of the AIDS
Clinical Trials Group: presence of symptoms of infection or
inflammatory disease, presence of symptoms occurring after
initiation of antiretroviral therapy, demonstration of adequate
virological response to therapy (1 log10 decrease in viral load),
and presence of symptoms not explainable by a newly acquired
infection or inflammatory condition (table 4). Shelburne et al.
[3] used the following criteria to identify patients with immune
reconstitution syndrome: current receipt of antiretroviral ther-
apy, clinical evidence of an inflammatory process that is not
consistent with the usual course of an established infection or
a new infectious process, increasing CD4+ cell count, and de-
creasing HIV-1 RNA level. Conceptually, this definition is very
similar to ours. Both definitions incorporate a temporal rela-
tionship to the initiation of antiretroviral therapy, evidence of
response to therapy, and demonstration that the manifestations
of the disease cannot be explained in the context of the expected
course of a newly acquired opportunistic infection or illness.
We elected to remove an increase in CD4+ cell count as an
absolute criterion, because plasma levels do not necessarily re-
flect function. Indeed, some early reports of immune recon-
stitution syndrome were noted with administration of zido-
vudine monotherapy in the absence of an increase in CD4+ cell
count, suggesting that even small reductions in HIV replication
may be sufficient to produce immune reconstitution syndrome
[13–15]. In addition, some immune responses may be restored
before a rise in plasma CD4+ cell count is detected. Thus, we
propose that an increase in CD4+ cell count should be viewed
as supportive of the diagnosis rather than required for it. Path-
ological evidence of well-formed granulomas may also be re-
garded as evidence of a restored inflammatory response and
should also be considered to be supportive of the diagnosis of
immune reconstitution syndrome, because this is uncommon
in patients with severe immune deficiency due to AIDS.
This definition serves as a framework for considering the
diagnosis of immune reconstitution syndrome, but it is limited
by the absence of criteria for establishing that a restored im-
mune response has occurred. An increase in CD4+ cell count
is not an adequate marker of restored immune function, be-
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Figure 3. Receiver operating characteristic curve of diagnostic accuracy using clinical scores developed from classification and regression tree
analysis. In a scenario of a case patient having a score of 4 or 11 opportunistic infection, baseline CD8+ cell count of 468.5 cells/mm3, and
baseline hemoglobin level of 13.6 g/dL, the sensitivity and specificity for predicting immune reconstitution syndrome will be 78.57% and 87.50%,
respectively. In another scenario, in which a case patient has a score of 2 or 11 opportunistic infection, baseline CD8+ cell count of 1468.5 cells/
mm3, and baseline hemoglobin level of 10.2 g/dL, the sensitivity and the specificity for predicting immune reconstitution syndrome will be 92.86%
and 80.00%, respectively.
Table 4. Clinical definition of immune reconstitution syndrome in the context of HIV infection.
Required criterion Supportive criterion
Worsening symptoms of inflammation/infection Increase in CD4+ cell count of 25 cells/mm3
Temporal relationship with starting antiretroviral treatment Biopsy demonstrating well-formed granulomatous inflammation
or unusually exuberant inflammatory response
Symptoms not explained by newly acquired infection or disease
or the usual course of a previously acquired disease
1 log10 decrease in plasma HIV load
cause pathogen-specific responses may remain deficient despite
an increase in CD4+ cell count or may recover before a mea-
surable increase in CD4+ cell count [1]. Such considerations
highlight the need for better methods to demonstrate the res-
toration of immune responses to aid in the diagnosis of im-
mune reconstitution syndrome. One potential means to ac-
complish this would be to demonstrate pathological evidence
of an exuberant inflammatory response. The utility of this ap-
proach, however, is limited by the inability to obtain a biopsy
specimen in all clinical situations. Another approach may be
to identify laboratory tests, such as those for cytokines and
immunologic markers, that can demonstrate a restored im-
mune response. IL-6 and soluble IL-6 receptor levels have been
shown to be increased in HIV-infected patients with a history
of immune reconstitution syndrome, but the relationship be-
tween IL-6 and immune reconstitution syndrome is yet to be
determined [16]. The level of soluble CD30, a marker of a Th2-
predominant cytokine environment, has been shown to be el-
evated in patients with a history of cytomegalovirus-associated
immune reconstitution syndrome [17, 18]. Further delineation
of laboratory correlates with immune reconstitution syndrome
is needed.
Identifying clinical or laboratory predictors of immune re-
constitution syndrome would be useful in stratifying persons
at greater risk. Shelburne et al. [19] reviewed patients with a
history of infection with M. avium, M. tuberculosis, or Cryp-
tococcus species who developed immune reconstitution syn-
drome and noted the following risk factors: initiating antiret-
roviral therapy more proximal to the time of diagnosis of
opportunistic infections, being antiretroviral-naive at the time
of diagnosis of opportunistic infection, and having a more-
rapid initial decrease in HIV-1 RNA level in response to HAART
[16]. In our study, we demonstrated that a greater number of
prior opportunistic infections, a higher baseline CD8+ cell
count, and a lower baseline hemoglobin level are associated
with immune reconstitution syndrome. A greater number of
1646 • CID 2006:42 (1 June) • HIV/AIDS
prior opportunistic infections may signify the presence of sig-
nificant residual antigens that may confer increased risk for
immune reconstitution syndrome. This idea is consistent with
the finding of Shelburne et al. [19] that patients who start
antiretroviral therapy in close proximity to the diagnosis of an
opportunistic infection are at increased risk for immune re-
constitution syndrome. We could not confirm, however, that
time from diagnosis of an opportunistic infection to initiation
of antiretroviral therapy was predictive of the development of
immune reconstitution syndrome (data not shown). Lower he-
moglobin levels may be a reflection of more advanced disease,
presence of a coinfecting pathogen affecting the bone marrow,
or greater severity of illness. Likely, they are an indirect marker
associated with the development of immune reconstitution syn-
drome. CD8+ cell counts likely represent the presence of im-
mune activation. CART analysis demonstrated that it is possible
to develop a clinical model predictive for developing immune
reconstitution syndrome. However, it would be useful to de-
velop more refined models with greater sensitivity and speci-
ficity. The absence of a reference standard definition or specific
test also limits our ability to develop predictive models. For
these reasons, it is important that this model and future models
be validated in a prospective fashion.
In summary, it is possible to develop a standard clinical
definition to fit most cases of immune reconstitution syndrome.
Some cases of immune reconstitution syndrome may be dif-
ficult to distinguish from newly acquired infections, under-
scoring the need for better diagnostic tests. This is especially
true for the occurrence of dermatomal zoster after initiation
of antiretroviral therapy. It is also possible to define a clinical
model with predictive value for immune reconstitution syn-
drome. Thus, in patients with lower CD4+ cell counts (!100
cells/mm3), the likelihood of immune reconstitution syndrome
may be predicted by a history of more frequent opportunistic
infections, higher CD8+ cell counts, and lower hemoglobin lev-
els. Additional research to identify other risk factors for im-
mune reconstitution syndrome and to develop confirmatory
diagnostic tests will help to refine and validate clinical models.
Use of the clinical model defined by CART analysis may provide
a basis for risk stratification of patients. Preemptive treatment
strategies will likely rely on prior identification of a population
at greater risk for immune reconstitution syndrome to mini-
mize the risk of exposing low-risk patients to potential harm.
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